Q901 for Advanced Solid Tumors
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 130 (estimated)
- Sponsor
- Qurient Co., Ltd. · Industry
This trial is looking for people with certain types of advanced cancer. Participants will receive a treatment called Q901 alone or with another drug and will be monitored for its safety and effectiveness.
You may be able to join if
- I have advanced or metastatic cancer that has not responded to treatment.
- I can have my cancer measured.
- I am aged 18 or older.
- I have a life expectancy of at least 3 months.
- I understand the study and sign a consent form.
You may not be able to join if
- I have serious heart problems or had a heart attack in the past 6 months.
- My heart has a significant electrical issue (QT interval).
- I have an active and uncontrolled infection.
- I have a poorly controlled autoimmune or inflammatory disease.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityMulticenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Loading trial locations…